Strategic Vision: A Global Pharma Company

North America US Generics: An established leader¹ 44 22.6% Number of products Market leader Albuterol Gx Market share 113 Q4FY22 36.6% YOY QoQ % of Sales -5.3% -10.2% LUPIN Managing our transition to Complex Generics US quarterly sales ($ mn) 202 Number of Products Top 3 by Market Share 195 184 181 172 3rd 160 196 Largest in the US Filings pending approval DMF filings (cumulative) Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 (by prescriptions¹) (cumulative) Launched 2 products in Q4 in US (gTaytulla and gRenagel) bringing the total marketed generic products to 166 Current pipeline includes 53 FTFs incl. 21 exclusive FTF awaiting USFDA approval 1. IQVIA Mar-22 7

View entire presentation